Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:administeredBy |
gptkb:rituximab
gptkb:obinutuzumab |
| gptkbp:approvalYear |
2016
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01XX52
|
| gptkbp:brand |
gptkb:Venclexta
gptkb:Venclyxto |
| gptkbp:CASNumber |
1257044-40-8
|
| gptkbp:chemicalFormula |
available
|
| gptkbp:developedBy |
gptkb:AbbVie
gptkb:Genentech |
| gptkbp:hasMolecularFormula |
C45H50ClN7O7S
|
| https://www.w3.org/2000/01/rdf-schema#label |
ABT-199
|
| gptkbp:indication |
gptkb:small_lymphocytic_lymphoma
gptkb:acute_myeloid_leukemia chronic lymphocytic leukemia |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
BCL-2 inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
gptkb:tumor_lysis_syndrome nausea diarrhea neutropenia thrombocytopenia |
| gptkbp:target |
BCL-2 protein
|
| gptkbp:bfsParent |
gptkb:5TBC
|
| gptkbp:bfsLayer |
8
|